The failure of a clinical trial often leads to a decrease in the stock price of a pharmaceutical company. In this case, Galecto's decision to discontinue the development of GB0139, a drug for Idiopathic Pulmonary Fibrosis, after failing to meet the primary endpoint in its Phase 2b trial, could lead to a decrease in its stock price. This is due to the potential loss of future revenues from the drug and the wasted resources in its development.